4 results about "Indapamide" patented technology

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The invention provides a sacubitril-valsartan sodium indapamide sustained-release tablet and a preparation method thereof, the sacubitril-valsartan sodium indapamide sustained-release tablet is of a double-layer tablet structure and comprises a first indapamide sustained-release layer and a second sacubitril-valsartan sodium quick-release layer, and the sacubitril-valsartan sodium indapamide sustained-release tablet can be prepared by adjusting the type and dosage of sustained-release materials in the indapamide sustained-release layer. According to the type and dosage of the disintegrating agent and the dosage of the adhesive in the sacubitril valsartan sodium quick release layer, the process of the double-layer tablet is stable, the release behavior of the double-layer tablet is similar to that of a single preparation, and the consistency of the curative effect of the medicine is ensured.

The application provides a sacubitril valsartan sodium indapamide sustained-release tablet and a preparation method thereof. The tablet is a double-layer tablet structure, comprising a first layer of an indapamide sustained-release layer and a second layer of a sacubitril valsartan sodium immediate-release layer. By adjusting the type and amount of the sustained-release material in the indapamide sustained-release layer, the type and amount of the disintegrant in the sacubitril valsartan sodium immediate-release layer and the amount of the binder, the double-layer tablet process is stable, the release behavior is similar to that of single preparation, and the consistency of the drug efficacy is ensured.

To provide a new effective and acceptable pharmaceutical composition for reducing hypertension.SOLUTION: (a) telmisartan, (b) indapamide, and (c) amlodipine besylate, wherein the dose of telmisartan is from about 8mg to about 12mg or from about 12mg to about 16mg, the dose of indapamide is from about 0. 5mg to about 0. 75mg or from about 0. 75mg to about 1. 0mg, and the dose of amlodipine besylate is from about 1mg to about 1. or from about 1. to about, and wherein the pharmaceutical composition further comprises one or more cholesterol lowering active agents. 5mg 5mg 2mg.SELECTED DRAWING: None